Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10997.144 | 0.9588 | 0.9351 | 1.2750 | |
| MCF7 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10997.144 | 0.8675 | 0.7890 | 1.2750 | |
| MCF7 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10997.144 | 0.7323 | 0.5664 | 1.2750 | |
| MCF7 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10997.144 | 0.6569 | 0.4384 | 1.2750 | |
| MCF7 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10997.144 | 0.6500 | 0.4265 | 1.2750 | |
| MCF7 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10997.144 | 0.5294 | 0.2145 | 1.2750 | |
| MCF7 | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 10997.144 | 0.0193 | -0.9097 | 1.2750 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 10998.144 | 0.9560 | 0.8926 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 10998.144 | 0.9961 | 0.9905 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10998.144 | 0.9080 | 0.7768 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10998.144 | 0.7861 | 0.4889 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10998.144 | 0.7045 | 0.3015 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10998.144 | 0.6213 | 0.1157 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10998.144 | 0.6684 | 0.2202 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10998.144 | 0.5146 | -0.1145 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 10998.144 | 0.0230 | -0.9804 | 0.8153 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 12206.144 | 0.9575 | 0.9135 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 12206.144 | 0.8397 | 0.6738 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 12206.144 | 0.7994 | 0.5920 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 12206.144 | 0.6747 | 0.3392 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 12206.144 | 0.6463 | 0.2817 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 12206.144 | 0.6429 | 0.2750 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 12206.144 | 0.5847 | 0.1573 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 12206.144 | 0.5147 | 0.0164 | 0.9811 | |
| MDA-MB-134-VI | HR+ | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 12206.144 | 0.2912 | -0.4314 | 0.9811 |